Bioisosterism: A Rational Approach in Drug Design.

Years of cumulative research can result in the development of a clinically useful drug, providing either a cure for a particular disease or symptomatic relief from a physiological disorder. A lead compound with a desired pharmacological activity may have associated with it undesirable side effects, characteristics that limit its bioavailability, or structural features which adversely influence its metabolism and excretion from the body. Bioisosterism represents one approach used by the medicinal chemist for the rational modification of lead compounds into safer and more clinically effective agents. The concept of bioisosterism is often considered to be qualitative and intuitive.1 The prevalence of the use of bioisosteric replacements in drug design need not be emphasized. This topic has been reviewed in previous years.2-5 The objective of this review is to provide an overview of bioisosteres that incorporates sufficient detail to enable the reader to understand the concepts being delineated. While a few popular examples of the successful use of bioisosteres have been included, the George Patani graduated with a B.Pharm. in 1992 from the College of Pharmaceutical Sciences, Mangalore University at Manipal, India. In 1996, he received his M.S. in Pharmaceutical Science at Rutgers University under the direction of Professor Edmond J. LaVoie. He is presently pursuing graduate studies in pharmaceutics. His current research interests are focused on drug design and controlled drug delivery.

[1]  Y. Martin,et al.  A practitioner's perspective of the role of quantitative structure-activity analysis in medicinal chemistry. , 1981, Journal of medicinal chemistry.

[2]  G. Flynn Substituent Constants for Correlation Analysis in Chemistry and Biology. , 1980 .

[3]  Novel Potassium Channel Openers: Synthesis and Pharmacological Evaluation of New N‐(Substituted‐3‐pyridyl)‐N′‐alkylthioureas and Related Compounds. , 1994 .

[4]  Rodney L. Johnson,et al.  Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogues of Pro-Leu-Gly-NH2. , 1993, Journal of medicinal chemistry.

[5]  A J Hopfinger,et al.  Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists. , 1994, Journal of medicinal chemistry.

[6]  W. Gould,et al.  Sulfonanilides. II. Analogs of Catecholamines. , 1967, Journal of medicinal chemistry.

[7]  U. Kristiansen,et al.  Electrophysiological studies of the GABAA receptor ligand, 4‐PIOL, on cultured hippocampal neurones , 1991, British journal of pharmacology.

[8]  B. Peskar On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs. , 1977, Biochimica et biophysica acta.

[9]  D. Sliskovic,et al.  Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. , 1991, Trends in pharmacological sciences.

[10]  G. Tsukamoto,et al.  Organic Phosphorus Compounds. Part 2. Synthesis and Coronary Vasodilator Activity of (Benzothiazolylbenzyl)phosphonate Derivatives. , 1989 .

[11]  J. Kraus,et al.  Isosterism and molecular modification in drug design: tetrazole analogue of GABA: effects on enzymes of the gamma-aminobutyrate system. , 1983, Pharmacological research communications.

[12]  Y. Hashimoto,et al.  New type inducers of differentiation of human HL-60 promyelocytic leukemia cells. Terephthalic anilides. , 1984, Chemical & pharmaceutical bulletin.

[13]  C. Yen,et al.  3,3-Diphenyl-3-(2-alkyl-1,3,4-oxadiazol-5-yl)propylcycloalkylamines, a novel series of antidiarrheal agents. , 1976, Journal of medicinal chemistry.

[14]  T. T. Chou,et al.  Benzyloxazolidine-2,4-diones as potent hypoglycemic agents. , 1991, Journal of medicinal chemistry.

[15]  P. Kelbaugh,et al.  Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors. , 1989, Journal of medicinal chemistry.

[16]  T. Uno,et al.  Synthesis of antimicrobial agents. 3. Syntheses and antibacterial activities of 7-(4-hydroxypiperazin-1-yl)quinolones. , 1990, Journal of medicinal chemistry.

[17]  H. J. Hess,et al.  Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues. , 1979, Journal of medicinal chemistry.

[18]  Y. Hashimoto,et al.  Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids. , 1989, Journal of medicinal chemistry.

[19]  M. Tominaga,et al.  Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[20]  R. Stanfield,et al.  Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 2. Modification of fatty acid anilide ACAT inhibitors: bioisosteric replacement of the amide bond. , 1993, Journal of medicinal chemistry.

[21]  T. Rimele,et al.  Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol. , 1986, Journal of medicinal chemistry.

[22]  Q. Sun,et al.  Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors. , 1995, Journal of medicinal chemistry.

[23]  R. Ball,et al.  Tryptophan-derived NK1 antagonists: conformationally constrained heterocyclic bioisosteres of the ester linkage. , 1995, Journal of medicinal chemistry.

[24]  J. Wessale,et al.  Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog. , 1994, Journal of medicinal chemistry.

[25]  G. Tsukamoto,et al.  Organic phosphorus compounds. 2. Synthesis and coronary vasodilator activity of (benzothiazolylbenzyl) phosphonate derivatives. , 1989, Journal of medicinal chemistry.

[26]  L. Iversen,et al.  A novel series of non‐quaternary oxadiazoles acting as full agonists at muscarinic receptors , 1990, British journal of pharmacology.

[27]  A. Lapucci,et al.  An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives. , 1985, Journal of medicinal chemistry.

[28]  M. Chlenov,et al.  Synthesis of indane derivatives as mechanism-based inhibitors of dopamine β-hydroxylase , 1995 .

[29]  G. Stankus,et al.  Characterization of the Cardiotonic Effects of Milrinone, a New and Potent Cardiac Bipyridine, on Isolated Tissues from Several Animal Species , 1983, Journal of cardiovascular pharmacology.

[30]  P. Seeman,et al.  The conformation of dopamine at its receptor: binding of monohydroxy-2-aminotetralin enantiomers and positional isomers. , 1979, Molecular Pharmacology.

[31]  R. Robinson,et al.  Œstrogenic Activity of Certain Synthetic Compounds , 1938, Nature.

[32]  S. Freedman,et al.  Synthesis and biological activity of 1,2,4-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors. , 1990, Journal of medicinal chemistry.

[33]  R. Ferone,et al.  Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones. , 1993, Journal of medicinal chemistry.

[34]  F. Bymaster,et al.  Novel Functional M1 Selective Muscarinic Agonists. Synthesis and Structure→Activity Relationships of 3‐(1,2,5‐Thiadiazolyl)‐1,2,5,6‐tetrahydro‐1‐methylpyridines. , 1992 .

[35]  R. K. Mishra,et al.  Dopamine receptor modulation by conformationally constrained analogues of Pro-Leu-Gly-NH2. , 1988, Journal of medicinal chemistry.

[36]  James E. Huheey,et al.  The Electronegativity of Groups , 1965 .

[37]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[38]  R. Lum,et al.  Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing a heterocyclic P1′-P2′ amide bond isostere , 1994 .

[39]  P. Bonnet,et al.  Modulation of leukocyte genetic expression by novel purine nucleoside analogues. A new approach to antitumor and antiviral agents. , 1993, Journal of medicinal chemistry.

[40]  D. Hoekman Exploring QSAR Fundamentals and Applications in Chemistry and Biology, Volume 1. Hydrophobic, Electronic and Steric Constants, Volume 2 J. Am. Chem. Soc. 1995, 117, 9782 , 1996 .

[41]  Y. Hashimoto,et al.  Differentiation inducers of human promyelocytic leukemia cells HL-60. Phenylcarbamoylbenzoic acids and polyene amides. , 1986, Chemical & pharmaceutical bulletin.

[42]  W. Jackson,et al.  Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain. , 1990, Journal of medicinal chemistry.

[43]  L. Whitby CHEMOTHERAPY OF BACTERIAL INFECTIONS , 1938 .

[44]  G. Mckenzie,et al.  Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene. , 1976, Journal of medicinal chemistry.

[45]  T. Honoré,et al.  Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships. , 1991, Journal of medicinal chemistry.

[46]  B. Kim,et al.  A new peptide bond surrogate: 2-isoxazoline in pseudodipeptide chemistry , 1992 .

[47]  R. Crossley,et al.  Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. , 1995, Journal of medicinal chemistry.

[48]  Heikkila Re,et al.  Pharmacological basis of therapeutics: dopamine receptors. , 1984 .

[49]  A. Black,et al.  Leukotriene B4‐like material in scale of psoriatic skin lesions , 1984, British journal of pharmacology.

[50]  R. Gillespie,et al.  2-(Oxadiazolyl)- and 2-(Thiazolyl)imidazo(1,2-a)pyrimidines as Agonists and Inverse Agonists at Benzodiazepine Receptors. , 1991 .

[51]  B. Baker Some Analogs of Hexestrol , 1943 .

[52]  A Burger,et al.  Isosterism and bioisosterism in drug design. , 1991, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[53]  C. Thornber,et al.  Isosterism and molecular modification in drug design , 1979 .

[54]  C. Martini,et al.  Conformationally restrained β-blocking oxime ethers: synthesis and β-adrenergic properties of diastereoisomeric anti and syn 2-(5′-isoxazolidinyl)-ethanolamines , 1992 .

[55]  D. R. Curtis,et al.  Synthesis and biological activity of a GABAA agonist which has no effect on benzodiazepine binding and of structurally related glycine antagonists. , 1987, Drug design and delivery.

[56]  P. Krogsgaard‐Larsen,et al.  GABA agonists and potential antagonists related to muscimol , 1979, Brain Research.

[57]  T. Himi,et al.  Retinobenzoic acids. 4. Conformation of aromatic amides with retinoidal activity. Importance of trans-amide structure for the activity. , 1989, Journal of medicinal chemistry.

[58]  P. Kelleher,et al.  Insulin-dependent? , 1985, The Lancet.

[59]  G. Cristalli,et al.  Synthesis and antitumor activity of 2-beta-D-ribofuranosyloxazole-4-carboxamide (oxazofurin). , 1990, Journal of medicinal chemistry.

[60]  S. Ross IN VIVO INACTIVATION OF CATECHOLAMINES IN MICE. , 2009, Acta pharmacologica et toxicologica.

[61]  Raymond C. F. Jones,et al.  Amide bond isosteres: Imidazolines in pseudopeptide chemistry , 1988 .

[62]  C. Swain,et al.  Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. , 1994, Journal of medicinal chemistry.

[63]  K. Suckling,et al.  Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. , 1985, Journal of lipid research.

[64]  R. Mishra,et al.  Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings , 1981, Peptides.

[65]  S. O’Rahilly,et al.  Pathogenesis of NIDDM--a disease of deficient insulin secretion. , 1988, Bailliere's clinical endocrinology and metabolism.

[66]  D. R. Curtis,et al.  DIHYDROMUSCIMOL, THIOMUSCIMOL AND RELATED HETEROCYCLIC COMPOUNDS AS GABA ANALOGUES , 1979, Journal of neurochemistry.

[67]  M. Fournié-Zaluski,et al.  New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. , 1994, Journal of medicinal chemistry.

[68]  F E Blaney,et al.  Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. , 1991, Journal of medicinal chemistry.

[69]  M. Dolan,et al.  8-Substituted O6-benzylguanine, substituted 6(4)-(benzyloxy)pyrimidine, and related derivatives as inactivators of human O6-alkylguanine-DNA alkyltransferase. , 1995, Journal of medicinal chemistry.

[70]  M. Kuhar,et al.  3-Aryl-2-(3'-substituted-1',2',4'-oxadiazol-5'-yl)tropane analogues of cocaine: affinities at the cocaine binding site at the dopamine, serotonin, and norepinephrine transporters. , 1993, Journal of medicinal chemistry.

[71]  P. Calabresi,et al.  Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine. , 1984, Cancer research.

[72]  M. Peterson,et al.  Spiro hydantoin aldose reductase inhibitors. , 1988, Journal of medicinal chemistry.

[73]  M. E. Goldberg Pharmacological and biochemical properties of drug substances , 1977 .

[74]  G. Lepage,et al.  BIOCHEMICAL AND CARCINOSTATIC EFFECTS OF 2'-DEOXYTHIOGUANOSINE. , 1964, Cancer research.

[75]  Corwin Hansch,et al.  The physicochemical approach to drug design and discovery (QSAR) , 1981 .

[76]  L. Waterbury,et al.  Synthesis and pharmacological evaluation of N,N-di-n-propyldopamine congeners containing phenolic bioisosteres. , 1987, Journal of pharmaceutical sciences.

[77]  M. Peterson,et al.  Sorbinil: a member of the novel class of spirohydantoin aldose reductase inhibitors. , 1986, Metabolism: clinical and experimental.

[78]  F. Labrie,et al.  Synthesis and in vitro evaluation of 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17 beta-carboxamides as 5 alpha-reductase inhibitors and antiandrogens. , 1995, Journal of medicinal chemistry.

[79]  Christopher A. Lipinski,et al.  Chapter 27. Bioisosterism in Drug Design , 1986 .

[80]  R. Olsen,et al.  GABAA receptor channels. , 1994, Annual review of neuroscience.

[81]  D. R. Curtis,et al.  STRUCTURE AND BIOLOGICAL ACTIVITY OF A SERIES OF CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA , 1975, Journal of neurochemistry.

[82]  N. Ackerman,et al.  Synthesis and antiinflammatory and analgesic activity of 5-aroyl-6-(methylthio)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-ca rboxyl ic acids and 1-methyl-4-(methylthio)-5-aroylpyrrole-2-acetic acids. , 1989, Journal of medicinal chemistry.

[83]  F. Muggia Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy , 2011, Cancer treatment and research.

[84]  Baldev Singh,et al.  Synthesis of analogs of amrinone: 4-(3,4-Disubstitutedphenyl)pyridines and derivatives thereof , 1991 .

[85]  W. Brouillette,et al.  3-Amino-5,5-dimethylhexanoic acid. Synthesis, resolution, and effects on carnitine acyltransferases. , 1994, Journal of medicinal chemistry.

[86]  C. Braestrup,et al.  Oxadiazoles as bioisosteric transformations of carboxylic functionalities. II , 1996 .

[87]  G. Metcalf,et al.  Drug Design via Pharmacophore Identification. Dopaminergic Activity of 3H- Benz[e]indol-8-amines and Their Mode of Interaction with the Dopamine Receptor. , 1986 .

[88]  W. Dallas,et al.  Catalytic role of histidine 147 in Escherichia coli thymidylate synthase. , 1989, The Journal of biological chemistry.

[89]  A. Schousboe,et al.  GABAA receptor agonists, partial agonists, and antagonists. Design and therapeutic prospects. , 1994, Journal of medicinal chemistry.

[90]  D. Baccanari,et al.  Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. , 1995, Journal of medicinal chemistry.

[91]  J. Kemp,et al.  Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. , 1994, Journal of medicinal chemistry.

[92]  W. Stenson,et al.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. , 1984, Gastroenterology.

[93]  Ruth E. McDermott,et al.  Novel thiazolidine-2,4-diones as potent euglycemic agents. , 1992, Journal of medicinal chemistry.

[94]  K. Bogeso,et al.  Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity. , 1994, Journal of medicinal chemistry.

[95]  Y. Hashimoto,et al.  Chalcone carboxylic acids. Potent differentiation inducers of human promyelocytic cells HL-60. , 1985, Chemical & pharmaceutical bulletin.

[96]  R. DeFronzo The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[97]  J. Metzger,et al.  Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan. , 1995, Journal of medicinal chemistry.

[98]  L. Field,et al.  Steric effects. A study of a rationally designed system , 1980 .

[99]  R. D. Dyer,et al.  Synthesis and Biological Evaluation of 5-((3,5-Bis(1,1-dimethylethyl)- 4-hydroxyphenyl)methylene)oxazoles, -thiazoles, and -imidazoles: Novel Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors with Antiinflammatory Activity. , 1994 .

[100]  Y. Hashimoto,et al.  Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60. , 1990, Journal of medicinal chemistry.

[101]  D. Dunn,et al.  Analysis of pilocarpine and isopilocarpine in ophthalmic solutions by normal-phase high-performance liquid chromatography. , 1981, Journal of pharmaceutical sciences.

[102]  A. Martinelli,et al.  Molecular orbital studies on the mechanism of drug-receptor interaction. 2. beta-Adrenergic drugs. An approach to explain the role of the aromatic moiety. , 1977, Journal of medicinal chemistry.

[103]  E. De Clercq,et al.  Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. , 1995, Journal of medicinal chemistry.

[104]  J. Sredy,et al.  Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat. , 1989, Journal of medicinal chemistry.

[105]  G. Rajakumar,et al.  Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position. , 1986, Journal of medicinal chemistry.

[106]  P. Krogsgaard‐Larsen,et al.  Heterocyclic analogues of GABA: chemistry, molecular pharmacology and therapeutic aspects. , 1985, Progress in medicinal chemistry.

[107]  J. Golden,et al.  THE PRIMARY SITE OF INHIBITION BY 6-MERCAPTOPURINE ON THE PURINE BIOSYNTHETIC PATHWAY IN SOME TUMORS IN VIVO. , 1963, Cancer Research.

[108]  F. Naguib,et al.  Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. , 1993, Cancer research.

[109]  E. Corey,et al.  Structure of leukotriene C. Identification of the amino acid part. , 1979, Biochemical and biophysical research communications.

[110]  H. Brown,et al.  The Structure and Toxicity of DDT Insecticides , 1953 .

[111]  R. K. Mishra,et al.  Interaction of l‐Prolyl‐l‐Leucyl Glycinamide with Dopamine D2 Receptor: Evidence for Modulation of Agonist Affinity States in Bovine Striatal Membranes , 1988, Journal of neurochemistry.

[112]  M. Forest,et al.  A novel class of cardiotonic agents: synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties. , 1992, Journal of medicinal chemistry.

[113]  D. R. Curtis,et al.  A new class of GABA agonist , 1977, Nature.

[114]  R. J. Bontems,et al.  Bicyclic thiazolidine lactam peptidomimetics of the dopamine receptor modulating peptide Pro-Leu-Gly-NH2. , 1993, Journal of medicinal chemistry.

[115]  M. Raiteri,et al.  Multiple GABAB receptors. , 1993, Trends in pharmacological sciences.

[116]  L. Thibault,et al.  A bio-assay for the concomitant assessment of the antiphlogistic and thymolytic activities of topically applied corticoids. , 1965, Endocrinology.

[117]  P. Krogsgaard‐Larsen,et al.  Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure–Activity Relationships and Therapeutic Potential , 1988 .

[118]  S. Moreland,et al.  Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines. , 1990, Journal of medicinal chemistry.

[119]  In vivo characterisation of novel efficacious muscarinic receptor agonists. , 1990, European journal of pharmacology.

[120]  A. Larsen,et al.  A New Bio-isostere : Alkylsulphonamidophenethanolamines , 1964, Nature.

[121]  R. Krell,et al.  A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. , 1990, Journal of medicinal chemistry.

[122]  Thomas Kolter,et al.  Peptidomimetics for Receptor Ligands. Discovery, Development, and Medical Perspectives , 1993 .

[123]  Thomas Kolter,et al.  Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives , 1993 .

[124]  A. Maycock,et al.  Inhibition of human leukocyte elastase. 3. Synthesis and activity of 3'-substituted cephalosporins. , 1990, Journal of medicinal chemistry.

[125]  E Falch,et al.  A novel class of conformationally restricted heterocyclic muscarinic agonists. , 1986, Journal of medicinal chemistry.

[126]  S E Ealick,et al.  Structure-based design of inhibitors of purine nucleoside phosphorylase. , 1995, Acta crystallographica. Section D, Biological crystallography.

[127]  A. Treasurywala,et al.  Novel inhibitors of the nuclear factor of activated T cells (NFAT)-mediated transcription of beta-galactosidase: potential immunosuppressive and antiinflammatory agents. , 1995, Journal of Medicinal Chemistry.

[128]  D. Roberts An isotopic assay for thymidylate synthetase. , 1966, Biochemistry.

[129]  Gabriele Cruciani,et al.  Principal Properties for Aromatic Substituents. A Multivariate Approach for Design in QSAR , 1989 .

[130]  A. Black,et al.  The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. , 1984, The Journal of investigative dermatology.

[131]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[132]  J. L. Howard,et al.  Benzodiazepine receptor binding activity of 6,9-disubstituted purines. , 1989, Journal of medicinal chemistry.

[133]  C. Kaiser,et al.  Adrenergic agents. 1. Synthesis and potential beta-adrenergic agonist activity of some catecholamine analogs bearing a substituted amino functionality in the meta position. , 1974, Journal of medicinal chemistry.

[134]  I. Langmuir ISOMORPHISM, ISOSTERISM AND COVALENCE. , 1919 .

[135]  J. Mond,et al.  8-Hydroxyguanosine and 8-methoxyguanosine possess immunostimulating activity for B lymphocytes. , 1985, Cellular immunology.

[136]  U. Kristiansen,et al.  Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol. , 1995, Journal of medicinal chemistry.

[137]  M. Kimmey NSAID, ulcers, and prostaglandins. , 1992, The Journal of rheumatology. Supplement.

[138]  Y. Hashimoto,et al.  Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. , 1988, Journal of medicinal chemistry.

[139]  H. Takahashi,et al.  Inhibition of two copper-containing enzymes, tyrosinase and dopamine beta-hydroxylase, by L-mimosine. , 1977, Molecular pharmacology.

[140]  A. Lapucci,et al.  Molecular design, synthesis, and antiinflammatory activity of a series of beta-aminoxypropionic acids. , 1990, Journal of medicinal chemistry.

[141]  D. A. Walsh,et al.  Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds. , 1989, Journal of medicinal chemistry.